Development of Novel Cancer Immunotherapy Targeting Mutated Genes: Identification of Antigen Epitopes Derived from the Mutated KRAS and EGFR Genes.

针对致癌突变基因的个性化癌症治疗目前正在开发中。由于突变基因被宿主免疫系统识别为外来基因，它们可能是癌症免疫治疗的合适靶点。在目前的研究中，我们已经确定了两个源于表皮生长因子受体(EGFR)T790M突变的抗原表位和一个来自KRAS(G12V)突变的抗原表位，前者是已知在非小细胞肺癌中导致对吉非替尼耐药的基因，后者在结直肠癌中经常被检测到。我们的结果可能为治疗携带这些突变的难治性晚期癌症患者提供一种新的免疫治疗方法，并可能导致针对突变基因的个性化免疫治疗的发展。

Personalized cancer treatments targeting oncogenic mutated genes are currently developing. Since mutated genes are recognized as foreign by the host immune system, they might be an appropriate target for cancer immunotherapy. In the current study, we have identified two antigen epitopes derived from the epidermal growth factor receptor (EGFR) T790M mutation, which is known to cause resistance to gefitinib in non-small cell lung cancer, and one antigen epitope derived from the KRAS (G12V) mutation, which is frequently detected in colorectal cancer. Our results could provide a novel immunotherapeutic approach for treatment against refractory advanced cancer patients with these mutations, and might lead to development of "personalized immunotherapy targeting mutated genes".